



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875

ABN: 51 094 468 318

24 March 2015

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY NSW 2000

RESAPP COMMENCES CLINICAL TRIAL AT JOONDALUP HEALTH CAMPUS

The Directors of Narhex Life Sciences Limited ("**Narhex**" or the "**Company**" ASX: **NLS**) are pleased to announce that ResApp Diagnostics Pty Ltd ("**ResApp**") has enrolled its first patient at Joondalup Health Campus ("**JHC**"), the largest hospital in Perth's Northern suburbs. The trial will gather data from approximately 150 patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma as well as broadening the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions. Preliminary results from this trial are expected within three months.

ResApp is currently finalising ethics approval to commence an additional trial at a second major Australian hospital that will greatly increase the speed in which patient data can be acquired.

Diane Jones, Deputy CEO at JHC said, "Joondalup Health Campus is very pleased to be involved in this ground-breaking study with ResApp and The University of Queensland with whom we share an interest in digital healthcare being incorporated into the general practice of medicine".

The commencement of the trial at Joondalup Health Campus was featured on Channel 7's Today Tonight on Monday, 23 March 2015.

Narhex has executed a formal Share Sale Agreement to acquire 100% of ResApp subject to satisfaction of conditions precedent including recompliance with Chapters 1 and 2 of the ASX Listing Rules. The Transaction will include a capital raising of at least \$2,500,000 to provide funding for ResApp and working capital for the Company.



About ResApp

ResApp through the exclusive licence it has been granted by the University of Queensland (“UQ”) is developing mobile medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone to diagnose and measure the severity of a respiratory condition. The algorithm has been tested for pneumonia and asthma diagnosis in a clinical proof of concept study of 91 patients by UQ through funding from the Bill and Melinda Gates Foundation. Addressable markets for this technology include the following:

1. At-home diagnosis and management of respiratory disease through direct sales to app consumers;
2. Licensing to large telehealth providers for “in consultation” diagnosis and assessment over mobile or the web; and
3. Working with organisations such as the World Health Organisation (WHO) to deliver tools for low-cost diagnosis and management of respiratory illness in the developing world.

The technology has been licensed to ResApp via UQ’s main commercialisation company UniQuest Pty Ltd (“UniQuest”). UniQuest is among the global leaders in commercialisation of university technologies and annual sales of products using UQ technology and licensed by UniQuest is approximately \$3b.

ResApp’s vision is to empower consumers to self-diagnose and manage respiratory disease by providing effective, affordable and practical mHealth apps without the need for additional hardware. Patients will be more informed about their health and be able to work more closely with their doctor to achieve better health outcomes. Cough is the most common single reason for a doctor visit, and in the US, over 100m primary care physician visits result in diagnosis of a respiratory disease. 15% of the world’s population suffer from chronic respiratory or pulmonary diseases such as asthma and COPD (chronic obstructive pulmonary disease), which require day-to-day disease management. The company will initially target a range of respiratory diseases including pneumonia, bronchitis, COPD and asthma and plans to expand its technology portfolio to encompass the entire spectrum of respiratory disease.

According to a recent Rock Health report, US venture capital investment in mHealth for the first half of 2014 represented \$2.4b, exceeding the total invested in 2013. Accenture recently predicted funding for digital health startups will reach \$6.5b in 2017.

Adam Sierakowski
Chairman

Contact:
Brian Leedman
Director, ResApp Diagnostics
M: 041 228 1780
E: b.leedman@iinet.net.au